Blood
Articles in this Issue
Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia
Abstract Introduction: For decades, standard upfront treatment for acute myeloid leukemia (AML) among fit patients (pts) has been intensive...
Inference of complex evolutionary histories of somatic mutations using bayesian stochastic character mapping
Abstract Introduction: Phylogenetic inference provides insight into the evolutionary mechanisms that shape hematopoietic progenitor populati...
Transplant outcomes of b acute lymphoblastic leukemia treated with inotuzumab ozogamicin with mini–Hyper-CVD based chemo-immunotherapy
Abstract Introduction Introduction of inotuzumab ozogamicin (InO), has changed the landscape of salvage treatment in patients with relapsed/...
Enhanced risk stratification in AML through integrated mutation and CNV profiling: Insights from Uruguay
Abstract Background: Accurate risk stratification in acute myeloid leukemia (AML) increasingly depends on integrated cytogenetic and molecul...
Mechanism of let-7c/HMGA2 signaling regulation mediated by DNA methylation in multiple myeloma
Abstract Background: multiple myeloma(MM) represents the second most common hematological malignancy characterized by the infiltration of th...
Clinical characteristics and prognosis analysis of autologous hematopoietic stem cell transplantation in 33 patients with HIV-associated lymphoma: A multicenter real-world retrospective study from China (CALL-005 Study)
Abstract In the era of combination antiretroviral therapy (cART), patients with HIV-associated lymphoma (HAL) can tolerate higher-intensity...
Real-world analysis of infection timing and burden in multiple myeloma patients treated with teclistamab
Abstract Background Teclistamab, a BCMA x CD3 bispecific antibody, is a highly effective novel therapeutic option for pa...
High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective mixed methods study.
Abstract Background Financial toxicity (FT) is defined as the negative financial consequences that pts and their families experience as a re...
Outcomes of clinical trial screening in patients with Myelodysplastic Syndromes and chronic myelomonocytic leukemia
Abstract Background: Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are hematologic malignancies characterized by...
Fludarabine and cytarabine is not superior to high dose cytarabine as consolidation therapy in standard risk AML in children: Results from the international Phase III MyeChild01 trial
Abstract Introduction MRC AML 15 reported that high dose cytarabine (HD AraC) was not inferior to an anthracycline containing regimen as con...
Outcomes of patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant stratified by the 2025 ims/IMWG risk classification
Abstract Introduction: Despite significant improvement in the survival of patients with newly diagnosed multiple myeloma (NDMM), a subset of...
Tyrosine kinase inhibitors, low intensity chemotherapy and allohct for adults with Philadelphia-positive acute lymphoblastic leukemia. Results of the polish adult leukemia group (PALG) ALL7 protocol
Abstract Introduction The prognosis of patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) improved with the introduc...
Sex-based disparities in MPN treatment patterns: A study of 1167 patients from the Quebec MPN registry
Abstract Background: Sex and gender have emerged as fundamental modifiers of disease biology, phenotype, and prognosis in myeloproliferative...
Delayed neurotoxicity, enterocolitis, and BCMA-CART-associated immune-related adverse events (CirAE) are caused by CD4+ CAR T-cells
Abstract Introduction. B-cell maturation antigen (BCMA)–directed CAR T-cell therapies (CART) are approved for second or third-line treatment...
Real-world data comparison of asciminib 40 mg twice daily vs. 80 mg once daily in chronic myeloid leukemia patients
Abstract Introduction: Asciminib (ASC) is a first-in-class Specifically Targeting the ABL Myristoyl Pocket (STAMP) inhib...
Differential trends in survival after allogeneic transplantation for MDS and MDS/MPN in a real-world experience
Abstract Introduction Recent advances in allogeneic hematopoietic stem cell transplantation (allo-HSCT) strategies and supportive care may ha...
Tracking clonal dynamics, tolerance, and adverse events after CD45-ADC–Conditioned autologous HSPC transplantation in rhesus macaques
Abstract Compared to total body irradiation (TBI) or chemotherapy, antibody-drug conjugate (ADC)–based transplant conditioning offers a more...
Baseline intratumoral CD4⁺ T-cell abundance and frequency correlates with durable clinical response to acalabrutinib, venetoclax, and obinutuzumab (AVO) treatment in Mantle Cell Lymphoma
Abstract Background: Mantle cell lymphoma (MCL) is a heterogeneous and currently incurable B-cell malignancy. As the tumor immune microenviro...
The effect of Medicaid expansion on survival outcomes among individuals with chronic myeloid leukemia
Abstract Background: Chronic Myeloid Leukemia (CML) is a rare hematologic malignancy primarily affecting older adults, with a median age at...
Clinical study of single-center PDT-ALL-2016 regimen in the treatment of KMT2A-rearranged acute lymphoblastic leukemia
Abstract Objective:To investigate the efficacy and prognostic factors of single-center PDT-ALL-2016 regimen in the treatment of patients wit...
Real-time tracking of RNA splicing in aged bone marrow hematopoietic stem and progenitor cells
Abstract Background RNA splicing is a critical regulator of hematopoietic stem and progenitor cell (HSPC) function and leukemogenesis. We pre...
Small molecule-regulated BCMA-CAR expression switch enables precise control of trispecific BCMA/CD20/CD79b targeting PSC-NK cell function against B cell-related disorders
Abstract Chimeric antigen receptor (CAR) cell therapy represents a significant advancement in immunotherapy against hematologic malignancies...
Impact of midostaurin in younger AML patients intensively treated with high-dose anthracycline
Abstract Introduction: Midostaurin (MIDO) was approved by the FDA in 04/2017 for the treatment of FLT3 mutated AML patients in combination w...
Multiple reciprocal interactions within B-cell receptor and AKT signaling pathways regulate response to EZH2 inhibition in germinal center-derived diffuse large B-cell lymphoma
Abstract Introduction. Enhancer of Zeste Homolog 2 (EZH2), which trimethylates Histone 3 at lysine 27 (H3K27me3), is frequently affected by...
A multicentre Phase I clinical trial demonstrates manufacturing feasibility, safety and activity of novel humanized BCMA-directed CAR-T cell therapy.
Abstract Background: BCMA directed CAR-T cell therapies have shown durable responses and improved outcomes in relapsed/refractory multiple m...